ANAB:NSD-AnaptysBio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.79

Change

0.00 (0.00)%

Market Cap

USD 0.71B

Volume

0.17M

Average Target Price

USD 29.50 (+14.39%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.95B 22.22 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.85B 18.84 14.36
MRNA Moderna, Inc

N/A

USD50.27B N/A N/A
SGEN Seagen Inc

N/A

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

N/A

USD27.10B 28.74 26.73
RPRX Royalty Pharma plc

N/A

USD26.01B 22.60 9.61
BNTX BioNTech SE

N/A

USD25.27B -99,999.99 N/A
BGNE BeiGene, Ltd

N/A

USD25.02B N/A N/A
GMAB Genmab A/S

N/A

USD23.59B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ANAB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.71% 76% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.71% 76% C 83% B
Trailing 12 Months  
Capital Gain 91.18% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.18% 78% C+ 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.71% N/A N/A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.71% N/A N/A 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 128.00% N/A N/A 7% F
Risk Adjusted Return 20.09% N/A N/A 46% F
Market Capitalization 0.71B 69% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.87 81% B- 58% F
Price / Cash Flow Ratio -10.15 64% D 79% C+
EV/EBITDA 0.11 78% C+ 96% A
Management Effectiveness  
Return on Equity -18.91% 87% B+ 36% F
Return on Invested Capital -23.81% 81% B- 27% F
Return on Assets -11.88% 84% B 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.47 33% F 19% F
Short Percent 22.28% 8% F 9% F
Beta 0.40 89% B+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector